BG103808A - Methods and compositions for modulation responsiveness to corticosteroids - Google Patents
Methods and compositions for modulation responsiveness to corticosteroidsInfo
- Publication number
- BG103808A BG103808A BG103808A BG10380899A BG103808A BG 103808 A BG103808 A BG 103808A BG 103808 A BG103808 A BG 103808A BG 10380899 A BG10380899 A BG 10380899A BG 103808 A BG103808 A BG 103808A
- Authority
- BG
- Bulgaria
- Prior art keywords
- corticosteroid
- antagonist
- patient
- antibody
- another
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Genetics & Genomics (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The methods are used for the treatment of different inflammatory and immunological diseases and disorders. They modulate the patient's reaction against corticostreroids. A form is applied which antagonzes a target regulating the IFN-gamma production together with a corticosteroid so that the patient's reaction to the corticosteroid is modulated in comparison with the individual administration of a corticosteroid. According to an option of implementation the form is IL-18 antagonist. In another option the form is interleucine-12 (IL-12) antagonist. The form can also be NK cellular antagonist. According to another preferable implementation the form is inhibitor of the caspase family protease, preferably ICE inhibitor. In another implemenmtation the foirm is anti- IL-12 monoclonal antibody. The form can be anti-asialo-GM1 antibody or NH1.1 antibody. Other perferable forms are phosphodiesterase IV inhibitors and beta-2 agonists. Pharmaceutical compositions are also developed including a form which antagonizes a target which regulates the production of IFN-gamma organism of the patient together with a corticosteroid and a pharmaceutically acceptable carrier. The preferable composition includes ICE inhibitor, corticosteroid and a pharmaceutically acceptable carrier. 86 claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/820,692 US6054487A (en) | 1997-03-18 | 1997-03-18 | Methods and compositions for modulating responsiveness to corticosteroids |
US1634698A | 1998-01-30 | 1998-01-30 | |
PCT/US1998/004916 WO1998041232A2 (en) | 1997-03-18 | 1998-03-12 | Compositions for modulating responsiveness to corticosteroids |
Publications (1)
Publication Number | Publication Date |
---|---|
BG103808A true BG103808A (en) | 2000-07-31 |
Family
ID=26688484
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BG103808A BG103808A (en) | 1997-03-18 | 1999-10-13 | Methods and compositions for modulation responsiveness to corticosteroids |
Country Status (20)
Country | Link |
---|---|
EP (1) | EP0998300A1 (en) |
JP (1) | JP2002504091A (en) |
KR (1) | KR20000076420A (en) |
CN (1) | CN1269722A (en) |
AU (1) | AU734756B2 (en) |
BG (1) | BG103808A (en) |
BR (1) | BR9810409A (en) |
CA (1) | CA2282845A1 (en) |
DE (1) | DE998300T1 (en) |
ES (1) | ES2146192T1 (en) |
HU (1) | HUP0104439A3 (en) |
ID (1) | ID22975A (en) |
IL (1) | IL131815A0 (en) |
NO (1) | NO994506L (en) |
NZ (1) | NZ337769A (en) |
PL (1) | PL336464A1 (en) |
SI (1) | SI20110A (en) |
SK (1) | SK122199A3 (en) |
TR (1) | TR199902615T2 (en) |
WO (1) | WO1998041232A2 (en) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US6830751B1 (en) | 1994-03-14 | 2004-12-14 | Genetics Institute, Llc | Use of IL-12 antagonists in the treatment of rheumatoid arthritis |
ZA95960B (en) * | 1994-03-14 | 1995-10-10 | Genetics Inst | Use of interleukin-12 antagonists in the treatment of autoimmune diseases |
US7704944B2 (en) | 1997-08-14 | 2010-04-27 | Yeda Research And Development Company Ltd. | Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis |
US7220717B2 (en) | 1997-08-14 | 2007-05-22 | Yeda Research And Development Company Ltd. | Interleukin-18 binding proteins, their preparation and use |
IL121860A0 (en) | 1997-08-14 | 1998-02-22 | Yeda Res & Dev | Interleukin-18 binding proteins their preparation and use |
US6184210B1 (en) | 1997-10-10 | 2001-02-06 | Cytovia, Inc. | Dipeptide apoptosis inhibitors and the use thereof |
AR015966A1 (en) * | 1997-10-17 | 2001-05-30 | Smithkline Beecham Corp | USE OF A PDE4 INHIBITOR COMPOUND FOR THE PREPARATION OF A USEFUL MEDICINAL PRODUCT FOR PRURITE TREATMENT |
ATE274920T1 (en) * | 1997-10-31 | 2004-09-15 | Wyeth Corp | USE OF ANTI-IL-12 ANTIBODIES IN TRANSPLANT REJECTION |
EP1516630A3 (en) * | 1997-10-31 | 2006-05-03 | Wyeth | Use of anti-il-12 antibodies in transplantation rejection |
WO1999025737A1 (en) * | 1997-11-19 | 1999-05-27 | Tanox Pharma B.V. | Compositions and methods for treatment of autoimmune diseases, using a monoclonal antibody to the interleukin-12 beta2-chain |
AU755273B2 (en) * | 1998-03-16 | 2002-12-05 | Cytovia, Inc. | Dipeptide caspase inhibitors and the use thereof |
WO2001045747A1 (en) * | 1998-11-27 | 2001-06-28 | Technion Research & Development Foundation Ltd. | Interferon gamma inducing factor based vaccine and use of same for protective immunity against multiple sclerosis |
DE69927520T2 (en) * | 1998-12-09 | 2006-06-22 | Protein Design Labs, Inc., Fremont | USE OF IL-12 ANTIBODIES FOR THE TREATMENT OF PSORIASIS |
CA2367340A1 (en) | 1999-03-16 | 2000-09-21 | Cytovia, Inc. | Substituted 2-aminobenzamide caspase inhibitors and the use thereof |
US7883704B2 (en) | 1999-03-25 | 2011-02-08 | Abbott Gmbh & Co. Kg | Methods for inhibiting the activity of the P40 subunit of human IL-12 |
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
DE19915465A1 (en) * | 1999-04-06 | 2000-10-19 | Apotech Res & Dev Ltd | Use of a caspase inhibitor to inhibit cell proliferation and use of one or more caspase inhibitors to treat diseases based on lymphocyte hyperproliferation or to suppress an immune response by lymphocytes |
CN1176941C (en) | 1999-04-09 | 2004-11-24 | 西托维亚公司 | Caspase inhibitors and the use thereof |
IL131047A0 (en) * | 1999-07-22 | 2001-01-28 | Yeda Res & Dev | Use of il-18 inhibitors |
JP2003508379A (en) | 1999-08-27 | 2003-03-04 | サイトビア インコーポレイテッド | Substituted α-hydroxy acid caspase inhibitors and uses thereof |
WO2001019373A2 (en) * | 1999-09-17 | 2001-03-22 | Basf Aktiengesellschaft | Methods and compositions for modulating responsiveness to corticosteroids |
US6566338B1 (en) | 1999-10-12 | 2003-05-20 | Cytovia, Inc. | Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death |
TWI373343B (en) | 2000-02-10 | 2012-10-01 | Abbott Gmbh & Co Kg | Antibodies that bind human interleukin-18 and methods of making and using |
JP2003535148A (en) * | 2000-06-06 | 2003-11-25 | グラクソ グループ リミテッド | How to treat cancer |
AU7250301A (en) * | 2000-06-22 | 2002-01-02 | Willy Ben Moussa Ben Mohammed | Use of glucocorticosteroids for producing a medicament to treat oligotrichia |
US20020025317A1 (en) * | 2000-07-20 | 2002-02-28 | Schering Ag | Bispecific monoclonal antibodies to IL-12 and IL-18 |
AU2000270300A1 (en) * | 2000-09-13 | 2002-03-26 | Isis Innovation Limited | Use of phosphodiesterase inhibitors for the treatment of anorectal disorders |
EP1188438A1 (en) * | 2000-09-15 | 2002-03-20 | Warner-Lambert Company | Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production |
EP1199074A1 (en) * | 2000-09-15 | 2002-04-24 | Warner-Lambert Company | Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production |
KR100857376B1 (en) * | 2001-01-29 | 2008-09-05 | 라보라토리스 세로노 에스.에이. | Use of il-18 inhibitors for the treatment and/or prevention of heart disease |
EA009125B1 (en) * | 2001-05-16 | 2007-10-26 | Йеда Рисерч Энд Дивелопмент Ко., Лтд. | Use of il-18 inhibitors for the treatment and/or prevention diseases characteristic to the systemic inflammatory response syndrome |
PL222211B1 (en) | 2001-06-26 | 2016-07-29 | Amgen Fremont Inc | Antibodies to opgl |
SI1448205T1 (en) * | 2001-10-05 | 2011-07-29 | Zalicus Inc | Combinations for the treatment of immunoinflammatory disorders |
JP2003342196A (en) * | 2002-05-31 | 2003-12-03 | Mukku:Kk | Composition for intravenous injection, method of production for the same and its preparation |
BR0314713A (en) * | 2002-09-24 | 2005-07-26 | Combinatorx Inc | Processes and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines. |
WO2004028545A1 (en) * | 2002-09-25 | 2004-04-08 | Astrazeneca Ab | A COMBINATION OF A LONG-ACTING β2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES |
WO2004067006A1 (en) * | 2003-01-27 | 2004-08-12 | Pharmacia Corporation | Combination of a pde iv inhibitor and a tnf-alpha antagonist |
US20050100965A1 (en) | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
EP1752159A4 (en) * | 2004-05-17 | 2009-07-01 | Univ Keio | Medicinal composition and therapeutic method |
GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
US7887802B2 (en) | 2004-07-16 | 2011-02-15 | Atsuo Sekiyama | IL-18 receptor antagonist and pharmaceutical composition containing the antagonist |
US20070287689A1 (en) * | 2004-10-13 | 2007-12-13 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic And/Or Preventive Agents For Chronic Skin Diseases |
BRPI0613034A8 (en) | 2005-07-14 | 2018-01-02 | Lipothera Inc | injectable formulation for fat tissue accumulation, injectable formulation and method for treating fat accumulation, and method for reducing fat tissue. |
PL2077830T3 (en) * | 2006-10-17 | 2013-04-30 | Lithera Inc | Methods, compositions, and formulations for the treatment of thyroid eye disease |
NZ578065A (en) | 2007-01-16 | 2012-09-28 | Abbott Lab | Methods for treating psoriasis with an antibody which binds to an epitope |
NZ598881A (en) | 2007-03-29 | 2013-11-29 | Abbvie Inc | Crystalline anti-human il-12 antibodies |
NZ587765A (en) | 2008-03-18 | 2013-02-22 | Abbott Lab | Methods for treating psoriasis |
US9132084B2 (en) | 2009-05-27 | 2015-09-15 | Neothetics, Inc. | Methods for administration and formulations for the treatment of regional adipose tissue |
CA2815374A1 (en) | 2010-11-24 | 2012-06-07 | Lithera, Inc. | Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging |
WO2015063669A1 (en) | 2013-10-30 | 2015-05-07 | Wockhardt Limited | Pharmaceutical compositions comprising combination of roflumilast and acebrophylline or pharmaceutically acceptable salts thereof |
AU2022353032A1 (en) * | 2021-09-22 | 2024-03-28 | Iolyx Therapeutics, Inc. | Methods of treating ocular inflammatory diseases |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3320125A (en) * | 1964-04-28 | 1967-05-16 | Merck & Co Inc | Inhalation aerosol composition |
DK0416950T3 (en) * | 1989-09-08 | 1993-10-11 | Glaxo Group Ltd | medications |
IL104068A (en) * | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant |
GB9202519D0 (en) * | 1992-02-06 | 1992-03-25 | Glaxo Group Ltd | Medicaments |
MX9304585A (en) * | 1992-07-31 | 1994-03-31 | Glaxo Group Ltd | PHARMACEUTICAL FORMULATION IN AEROSOL, CAN SUITABLE TO RELEASE THE FORMULATION AND INHALER OF DOSE DOSE THAT COMPRISES THE CAN. |
GB9426252D0 (en) * | 1994-12-24 | 1995-02-22 | Glaxo Group Ltd | Pharmaceutical composition |
GEP20002266B (en) * | 1995-04-14 | 2000-10-25 | Glaxo Wellcome Inc | Metered Dose Inhaler, the Inhaler System Comprising the Same and Method for Treatment of Respiratory Disturbances |
-
1998
- 1998-03-12 PL PL98336464A patent/PL336464A1/en unknown
- 1998-03-12 AU AU67604/98A patent/AU734756B2/en not_active Ceased
- 1998-03-12 JP JP54063398A patent/JP2002504091A/en active Pending
- 1998-03-12 NZ NZ337769A patent/NZ337769A/en unknown
- 1998-03-12 SI SI9820032A patent/SI20110A/en unknown
- 1998-03-12 CN CN98805124A patent/CN1269722A/en active Pending
- 1998-03-12 ES ES98912929T patent/ES2146192T1/en active Pending
- 1998-03-12 CA CA002282845A patent/CA2282845A1/en not_active Abandoned
- 1998-03-12 DE DE0998300T patent/DE998300T1/en active Pending
- 1998-03-12 EP EP98912929A patent/EP0998300A1/en not_active Withdrawn
- 1998-03-12 KR KR1019997008524A patent/KR20000076420A/en not_active Application Discontinuation
- 1998-03-12 BR BR9810409-8A patent/BR9810409A/en not_active IP Right Cessation
- 1998-03-12 SK SK1221-99A patent/SK122199A3/en unknown
- 1998-03-12 TR TR1999/02615T patent/TR199902615T2/en unknown
- 1998-03-12 WO PCT/US1998/004916 patent/WO1998041232A2/en not_active Application Discontinuation
- 1998-03-12 IL IL13181598A patent/IL131815A0/en unknown
- 1998-03-12 ID IDW991185A patent/ID22975A/en unknown
- 1998-03-12 HU HU0104439A patent/HUP0104439A3/en unknown
-
1999
- 1999-09-17 NO NO994506A patent/NO994506L/en unknown
- 1999-10-13 BG BG103808A patent/BG103808A/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO1998041232A2 (en) | 1998-09-24 |
AU734756B2 (en) | 2001-06-21 |
SI20110A (en) | 2000-06-30 |
HUP0104439A2 (en) | 2002-04-29 |
DE998300T1 (en) | 2001-03-01 |
HUP0104439A3 (en) | 2002-08-28 |
NO994506D0 (en) | 1999-09-17 |
WO1998041232A3 (en) | 2000-10-05 |
NO994506L (en) | 1999-11-17 |
NZ337769A (en) | 2002-09-27 |
CN1269722A (en) | 2000-10-11 |
ES2146192T1 (en) | 2000-08-01 |
EP0998300A1 (en) | 2000-05-10 |
CA2282845A1 (en) | 1998-09-24 |
PL336464A1 (en) | 2000-06-19 |
AU6760498A (en) | 1998-10-12 |
SK122199A3 (en) | 2000-12-11 |
IL131815A0 (en) | 2001-03-19 |
KR20000076420A (en) | 2000-12-26 |
ID22975A (en) | 1999-12-23 |
BR9810409A (en) | 2000-08-22 |
JP2002504091A (en) | 2002-02-05 |
TR199902615T2 (en) | 2000-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BG103808A (en) | Methods and compositions for modulation responsiveness to corticosteroids | |
WO2001019373A3 (en) | Methods and compositions for modulating responsiveness to corticosteroids | |
Nothnick | Treating endometriosis as an autoimmune disease | |
Murrell et al. | Nitric oxide activates metalloprotease enzymes in articular cartilage | |
HK1022440A1 (en) | Combination therapy using a tnf binding protein for treating tnf-mediated diseases | |
UA74325C2 (en) | HETEROCYCLIC INHIBITORS р38, PHARMACEUTICAL COMPOSITION CONTAINING THEM, AND A METHOD FOR TREATMENT WITH THEIR USE | |
EP1717251A3 (en) | Methods of therapy for B-cell malignancies using human anti-CD40 antibodies | |
EP1485381B8 (en) | Azolylaminoazine as inhibitors of protein kinases | |
MY117696A (en) | INHIBITORS OF p38 | |
AU1520195A (en) | Use of anti-tnf antibodies as drugs in treating diseases involving elevated interleukin-6 serum levels | |
AU2003220299A1 (en) | Azinylaminoazoles as inhibitors of protein kinases | |
AU2003218215A1 (en) | Azolylaminoazines as inhibitors of protein kinases | |
AU2003220300A1 (en) | Compositions useful as inhibitors of protein kinases | |
UA37244C2 (en) | Method for treating or preventing clinical disorders curable with progesterone in female patients | |
DE69625691D1 (en) | ADMINISTRATION OF PEPTIDYLHETEROCYCLES FOR THE TREATMENT OF THROMBINE IN RELATED DISEASES | |
ATE296799T1 (en) | P38 INHIBITORS | |
Goodrich et al. | Effect of intestinal epithelial cell cytokines on mucosal B-cell IgA secretion: enhancing effect of epithelial-derived IL-6 but not TGF-β on IgA+ B cells | |
BR9610480A (en) | Tumor necrosis factor alpha inhibition | |
MX9701820A (en) | PYRAZOLO[3,4-g]QUINOXALINE COMPOUNDS WHICH INHIBIT PDGF RECEPTOR PROTEIN TYROSINE KINASE. | |
WO2003054018A3 (en) | Anti-tirc7 antibodies in therapy of inflammatory diseases | |
MX2022001403A (en) | Methods of administering anti-siglec-8 antibodies and corticosteroids. | |
GEP20063774B (en) | Blocking Monoclonal Antibody to VLA-1 and Its Use for Treatment of Inflammatory Disorders | |
MD1521F2 (en) | Methods of thrombus forming inhibition, methods of treatment of thrombotic states, pharmaceutical compositions and kit for treatment of thrombotic states | |
Rosenbach et al. | Dermatologic therapeutics: thalidomide. A practical guide | |
DE60020970D1 (en) | MONOCLONAL ANTIBODY WITH SELECTIVE BINDING TO VGF AND USE FOR THE TREATMENT OF VGF DISEASES |